ClinicalTrials.gg

Polycystic Kidney, Autosomal Dominant clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 185 studies for Polycystic Kidney, Autosomal Dominant across more than 10 countries. 42 are recruiting or about to start. 172 of them are mainly about Polycystic Kidney, Autosomal Dominant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
94
Recruiting
30
Active, not recruiting
18
Status unknown
16
Terminated
13
Not yet recruiting
9

Phase

Phase 2
44
Phase 3
39
Phase 1
23
Phase 4
8
Early Phase 1
1

Where

United States
85
Italy
29
Germany
24
Netherlands
23
France
20
United Kingdom
20

Who develops what

Add Polycystic Kidney, Autosomal Dominant to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 7 companies, 8 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Jemincare, AstraZeneca and GlaxoSmithKline here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 28 Feb 2027 est.JMKX003142 · Jemincare · Phase 2 main aimNCT06800651 Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) — primary endpoint: Percentage Change of TKV from baseline to Week 52 · 135 enrolled
  • 22 Jul 2027 est.VX-407 · Vertex Pharmaceuticals Incorporated · Phase 2 main aimNCT07161037 Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) — primary endpoint: htTKV on MRI Over Time · 26 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Polycystic Kidney, Autosomal Dominant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SGLT2 inhibitors 1 open · Statins 1 open · mTOR inhibitors 10 · Tyrosine kinase inhibitors (TKIs) 4

Coming up

26studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger. 7 (23%) take children under 18. 2 (7%) are for women only and 1 (3%) for men only; 9 (30%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
104 (13%)4 (13%)
1828 (93%)26 (87%)
3027 (90%)26 (87%)
4025 (83%)24 (80%)
5023 (77%)23 (77%)
6518 (60%)18 (60%)
7512 (40%)12 (40%)
859 (30%)9 (30%)

Across all 185 studies, recruiting or not: 61% stop at 75 or younger and 51% at 65; 16% take children; 2% are for women only and 1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Polycystic Kidney, Autosomal Dominant studies take

Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 239 mo18–53 · 17 studies——
Interventional, no phase30 mo19–54 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 185. Browse all 185 → or search them.